HLA-Releasing Metalloproteinase in Allograft Rejection

Information

  • Research Project
  • 7025818
  • ApplicationId
    7025818
  • Core Project Number
    R01AI045761
  • Full Project Number
    5R01AI045761-05
  • Serial Number
    45761
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/1/2005 - 19 years ago
  • Project End Date
    2/28/2010 - 14 years ago
  • Program Officer Name
    MACCHIARINI, FRANCESCA
  • Budget Start Date
    3/1/2006 - 18 years ago
  • Budget End Date
    2/28/2007 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    5
  • Suffix
  • Award Notice Date
    4/21/2006 - 18 years ago

HLA-Releasing Metalloproteinase in Allograft Rejection

DESCRIPTION (provided by applicant): We have previously described the metalloproteinase-mediated pathway of soluble MHC class I release and proposed its role in transplantation. We found that the release of soluble MHC class I is mediated by a disintegrin and metalloprotease family member, ADAM17. Endothelial cells (EC) co-cultured with allogeneic T cells up-regulate specific activation markers and both the expression and activity of ADAM 17. This activation is driven by interferon-gamma and culminates in the release of soluble MHC class I proteins by EC. However, at least one other metalloproteinase distinct from ADAM17 is fully capable of releasing soluble MHC class I. Its activity may be regulated by cytokines in a tissue-specific manner. Screening of a human leukemia expression library with our mAb that blocks the release of soluble MHC class I led to identification of a novel protein BC036469 with yet unknown function. This ubiquitously expressed protein may participate in the mechanism of soluble MHC class I release by mediating specific enzyme/substrate interactions and its function may be regulated by cell-specific cytokines in different tissues. Three independent aims are designed to address these questions. First, we will identify cytokine-inducible metalloproteinases capable of processing MHC class I by using a panel of ADAM-deficient cell lines and by DNA microarray analysis. Second, the function of BC036469 protein will be determined by overexpressing wild type and deletion mutants, and by disrupting expression of the endogenous protein with specific siRNA. Finally, we will determine the sites required for productive enzyme/substrate interactions within alpha 3 and transmembrane domains of MHC class I and test the ability of specific peptides to inhibit the interaction. The predicted role of soluble MHC class I in antigen presentation will be tested using the trans-vivo delayed-type hypersensitivity assay in the linked suppression model of immune regulation by HLA-A2- restricted CD8 low avidity T regulator cells controlling transplantation tolerance.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    326780
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:326780\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PUBLIC HEALTH RESEARCH INSTITUTE
  • Organization Department
  • Organization DUNS
  • Organization City
    NEWARK
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    071033535
  • Organization District
    UNITED STATES